CLOVER HEALTH INVESTMENTS, CORP. /DE·4

Jun 18, 6:42 AM ET

Reynoso Jamie L. 4

4 · CLOVER HEALTH INVESTMENTS, CORP. /DE · Filed Jun 18, 2026

Research Summary

AI-generated summary of this filing

Updated

Clover Health (CLOV) CEO Jamie L. Reynoso Sells 2,360 Shares

What Happened
Jamie L. Reynoso, CEO (Medicare Advantage) of Clover Health Investments, sold 2,360 shares on 2026-06-17 in an open-market disposition. The weighted average sale price reported was $4.78 per share, for total proceeds of approximately $11,281. This was a sale (not a purchase or option exercise).

Key Details

  • Transaction date: 2026-06-17 (reported on Form 4 filed 2026-06-18). Filing appears timely.
  • Transaction type/code: Sale (S) — open market or private sale.
  • Shares sold: 2,360; weighted average price: $4.78; total proceeds ≈ $11,281.
  • Price range: shares were sold in multiple transactions at prices from $4.73 to $4.87 (inclusive).
  • Footnote: The sale was made under a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2026. The filer can provide a breakdown of shares sold at each separate price upon request.
  • Shares owned after transaction: not provided in the supplied data.

Context
A sale under a 10b5-1 plan is typically a preplanned transaction and does not necessarily reflect the insider’s current view of the company. For retail investors, purchases are often viewed as stronger signals than routine sales; this filing documents a routine, planned disposition.

Insider Transaction Report

Form 4
Period: 2026-06-17
Reynoso Jamie L.
CEO, Medicare Advantage
Transactions
  • Sale

    Class A Common Stock

    [F1]
    2026-06-17$4.78/sh2,360$11,2812,841,211 total
Footnotes (1)
  • [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $4.87, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Remarks:
Signature
/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso|2026-06-18

Documents

1 file
  • 4
    wk-form4_1781779319.xmlPrimary

    FORM 4